Figure 3.

In vivo recall responses to anti-PD-1 in Cxcr6^−/− mice are markedly compromised. (A) t-SNE plot showing distribution of T cell subsets before (left) or after (right) treatment with isotype control or anti-CD40 agonist. (B) Violin plot showing the expression of CXCR6 after treatment with isotype control or anti-CD40 agonist. (C) Schematic diagram of the anti-PD-1 treatment schedule. Mice were inoculated subcutaneously with MC38 tumor cells and were intraperitoneally treated with 200 µg of isotype control or anti-PD-1 antibodies on days 10/13/16 after tumor inoculation. (D) Tumor growth (n=6–9). (E) Proportions of intratumoral CD8⁺ T cells and cytokines produced was quantified from WT and Cxcr6^−/− mice treated with isotype or anti-PD-1. Data are presented as the mean±SEM. *P<0.05, **p<0.01, and ***p<0.001, ****p<0.0001; single cell RNA sequencing data were analyzed on website http://crcleukocytecancer-pkucn/.